YCBD Stock Analysis: Buy, Sell, or Hold?
YCBD - cbdMD, Inc. Common Stock
$0.66
-0.02 (-3.56%)
▼
5d:
-10.87%
30d:
-5.77%
90d:
-11.72%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
28d
Get Alerted When YCBD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: YCBD is down 10.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: YCBD is down 10.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: YCBD is currently trading at $0.66, which is considered oversold relative to its 30-day fair value range of $0.67 to $0.74.
Technical Outlook: Technically, YCBD is in a downtrend. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.00 (+204.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, YCBD is in a downtrend. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.00 (+204.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.67 -
$0.74
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 204.1% below Wall St target ($2.00)
- WARNING: Recommendation downgraded due to -10.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.67 -
$0.74
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.69
Resistance Level
$0.86
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.40
Wall Street Target
$2.00
(+204.1%)
Revenue Growth (YoY)
18.8%
Profit Margin
-13.3%
Share & Embed Analysis
Last updated: July 15, 2026 1:51 AM ET
Data refreshes hourly during market hours. Next update: 2:51 AM
Data refreshes hourly during market hours. Next update: 2:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is YCBD showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
